Matinas biopharma holdings announces positive end of phase 2 meeting with fda for mat9001 in severe hypertriglyceridemia

Matinas biopharma holdings inc - announces positive end of phase 2 meeting with fda for mat9001 in severe hypertriglyceridemia.matinas biopharma - official minutes of confirmed fda, co aligned on key next steps for mat9001's phase 3 development program.matinas biopharma holdings inc - on track to initiate its phase 3 program in h1 2021.
MTNB Ratings Summary
MTNB Quant Ranking